Can TRIESENCE® Injections be Used to Treat Uveitis?

February 20, 2013

In a recently commenced clinical trial, Clearside Biomedical, Inc. will be evaluating the effectiveness of treating uveitis by injecting TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL directly into the eye’s suprachoroidal space (SCS) via Clearside’s proprietary microneedle.

Clearside’s patented microinjection system is the only non-surgical application to introduce drugs into targeted eye tissue at the back of the eye via the SCS.

Click here for further details about this clinical trial.




Jump down to form below to submit your own comments

Comments are closed.